These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

388 related articles for article (PubMed ID: 34522111)

  • 21. Trends in Angiotensin-Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use among Those with Impaired Kidney Function in the United States.
    Murphy DP; Drawz PE; Foley RN
    J Am Soc Nephrol; 2019 Jul; 30(7):1314-1321. PubMed ID: 31167823
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A five-year comparison of the renal protective effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with non-diabetic nephropathy.
    Shoda J; Kanno Y; Suzuki H
    Intern Med; 2006; 45(4):193-8. PubMed ID: 16543688
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on serum potassium levels and renal function in ambulatory outpatients: risk factors analysis.
    Maddirala S; Khan A; Vincent A; Lau K
    Am J Med Sci; 2008 Oct; 336(4):330-5. PubMed ID: 18854676
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Distinct time courses of renal protective action of angiotensin receptor antagonists and ACE inhibitors in chronic renal disease.
    Matsuda H; Hayashi K; Saruta T
    J Hum Hypertens; 2003 Apr; 17(4):271-6. PubMed ID: 12692572
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect on the atherogenic marker plasminogen activator inhibitor type-1 of addition of the ACE inhibitor imidapril to angiotensin II type 1 receptor antagonist therapy in hypertensive patients with abnormal glucose metabolism: a prospective cohort study in primary care.
    Yajima K; Shimada A; Hirose H; Oikawa Y; Yamada S; Meguro S; Irie J; Irie S
    Clin Drug Investig; 2009; 29(12):811-9. PubMed ID: 19888787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prescriptions for angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and monitoring of serum creatinine and potassium in patients with chronic kidney disease.
    Wang PT; Huang YB; Lin MY; Chuang PF; Hwang SJ
    Kaohsiung J Med Sci; 2012 Sep; 28(9):477-83. PubMed ID: 22974666
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?
    Weir MR
    Clin Ther; 2007 Sep; 29(9):1803-24. PubMed ID: 18035185
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical pharmacokinetics of angiotensin II (AT1) receptor blockers in hypertension.
    Israili ZH
    J Hum Hypertens; 2000 Apr; 14 Suppl 1():S73-86. PubMed ID: 10854085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. New-onset diabetes and antihypertensive treatment.
    Grimm C; Köberlein J; Wiosna W; Kresimon J; Kiencke P; Rychlik R
    GMS Health Technol Assess; 2010 Mar; 6():Doc03. PubMed ID: 21289876
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Effect of diabetic management modes on diabetic nephropathy: a prospective study].
    Li J; Huang B; Wang S; Ji X; Yin J; Yang N; Zhai J; Kang W; Ma X
    Zhonghua Wei Zhong Bing Ji Jiu Yi Xue; 2019 Dec; 31(12):1497-1500. PubMed ID: 32029036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.
    Pathak JV; Dass EE
    Indian J Pharmacol; 2015; 47(2):148-52. PubMed ID: 25878372
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Receipt of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers among Medicare Beneficiaries with Diabetes and Hypertension.
    Wang J; Surbhi S; Kuhle JW
    J Pharm Health Serv Res; 2014 Mar; 5(1):67-74. PubMed ID: 24563667
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ACE-inhibitor or AT2-antagonist therapy of renal transplant recipients is associated with an increase in serum potassium concentrations.
    Mitterbauer C; Heinze G; Kainz A; Kramar R; Hörl WH; Oberbauer R
    Nephrol Dial Transplant; 2008 May; 23(5):1742-6. PubMed ID: 18234845
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Association of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Blockers With Severity of COVID-19: A Multicenter, Prospective Study.
    Hakeam HA; Alsemari M; Duhailib ZA; Ghonem L; Alharbi SA; Almutairy E; Sheraim NMB; Alsalhi M; Alhijji A; AlQahtani S; Khalid M; Barry M
    J Cardiovasc Pharmacol Ther; 2021 May; 26(3):244-252. PubMed ID: 33231487
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Long-term changes of renal function in relation to ace inhibitor/angiotensin receptor blocker dosing in patients with heart failure and chronic kidney disease.
    Fröhlich H; Nelges C; Täger T; Schwenger V; Cebola R; Schnorbach J; Goode KM; Kazmi S; Katus HA; Cleland JG; Clark AL; Frankenstein L
    Am Heart J; 2016 Aug; 178():28-36. PubMed ID: 27502849
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use Among Hypertensive US Adults With Albuminuria.
    Chu CD; Powe NR; McCulloch CE; Banerjee T; Crews DC; Saran R; Bragg-Gresham J; Morgenstern H; Pavkov ME; Saydah SH; Tuot DS;
    Hypertension; 2021 Jan; 77(1):94-102. PubMed ID: 33190561
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Urinary angiotensin-converting enzyme 2 in hypertensive patients may be increased by olmesartan, an angiotensin II receptor blocker.
    Furuhashi M; Moniwa N; Mita T; Fuseya T; Ishimura S; Ohno K; Shibata S; Tanaka M; Watanabe Y; Akasaka H; Ohnishi H; Yoshida H; Takizawa H; Saitoh S; Ura N; Shimamoto K; Miura T
    Am J Hypertens; 2015 Jan; 28(1):15-21. PubMed ID: 24842388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics of patients prescribed angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or the combination at an urban medical center.
    Masri G; Bledsoe K; Palacio C
    MedGenMed; 2007 Nov; 9(4):40. PubMed ID: 18311390
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Renal Effects and Associated Outcomes During Angiotensin-Neprilysin Inhibition in Heart Failure.
    Damman K; Gori M; Claggett B; Jhund PS; Senni M; Lefkowitz MP; Prescott MF; Shi VC; Rouleau JL; Swedberg K; Zile MR; Packer M; Desai AS; Solomon SD; McMurray JJV
    JACC Heart Fail; 2018 Jun; 6(6):489-498. PubMed ID: 29655829
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Low body mass index is a risk factor for hyperkalaemia associated with angiotensin converting enzyme inhibitors and angiotensin II receptor blockers treatments.
    Hirai T; Yamaga R; Fujita A; Itoh T
    J Clin Pharm Ther; 2018 Dec; 43(6):829-835. PubMed ID: 29908131
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.